

RECEIVED

10-31-03

GP 1646



NOV 05 2003

CASE 4-30868A/C1

TECH CENTER 1600/2900

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 987586952 US

Express Mail Label Number

October 30, 2003

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

BERNASCONI ET AL.

Examiner: M.T. Brannock

APPLICATION NO: 09/955,381

FILED: SEPTEMBER 18, 2001

FOR: USE OF GABA_B RECEPTOR LIGANDS FOR THE TREATMENT OF
NEURODEGENERATIVE DISEASES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

ELECTION OF SPECIES


Sir:

This is in response to the Official Action dated October 2, 2003.

The Examiner contends that the four uses as set forth on Page 2 of the Official Action are directed to patentably distinct species. Accordingly, the Examiner has required an election under 35 U.S.C. §121 to one of the four uses. In response thereto, Applicants elect the first use, viz., methods of treating Parkinson's disease. In this connection, Claims 1, 2, 4, 6-10, 12, 14 and 16 read on the "elected" use.

In view of the foregoing, an action on the merits of all claims which read on the "elected" use, viz., Claims 1, 2, 4, 6-10, 12, 14 and 16, is respectfully requested.

Respectfully submitted,


Joseph J. Borovian
Agent for Applicants
Reg. No. 26,631
(862) 778-7801

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080

JJB/lid

Encl.: Postcard

Date: October 30, 2003